VEGFA and neoplasm: Therefore, targeting VEGF with an active immunotherapy like HEBERSaVax is a strategic approach to simultaneously disrupt tumor vascularization and reverse immune suppression, potentially overcoming limitations of passive antibody therapies and creating a more favorable environment for antitumor immunity.